On down-regulation of the immune response to metastatic malignant melanoma

Cancer Immunology Immunotherapy

Volumn 48, Issue 5, 1999, Pages 253-262

  Håkansson, Annika ^a   Gustafsson, Bertil ^a   Krysander, Lennart ^a   Hjelmqvist, Bengt ^b   Rettrup, Björn ^b   Håkansson, Leif ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

chain; Down regulation; Immune response; Interferon ; Metastatic melanoma

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD80; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; FEMALE; GENES, MHC CLASS II; HUMANS; IMMUNOGLOBULIN GAMMA-CHAINS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; PORE FORMING CYTOTOXIC PROTEINS; TISSUE DISTRIBUTION;

EID: 0032773881     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050573     Document Type: Article

References (54)

1. 1. Aebershold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA (1991) Lysis of autologous melanoma cells by tumour infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 83:932
2. 2. Aoe T, Okamoto Y, Saito T (1995) Activated machrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881
3. 3. Azuma M, Lanier LL (1995) The role of CD28 costimulation in the generation of cytotoxic T lymphocytes. Curr Top Microbiol Immunol 198:59
4. 4. Barcy S, Wettendorf M, Leo O, Urbain J, Kruger M, Ceuppens JL, De Boer M (1995) FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Int Immunol 7:179
5. 5. Casado JA, Merino J, Cid J, Subira ML, Sanchez-Ibarrola A (1994) The type of interaction with Fc gamma R in human monocytes determines the efficiency of the generation of oxidative burst. Immunology 83:148
6. 6. Chen L, Mc Gowan P, Ashe S, Johnson J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumour immunogenicity determines the effect of B7 costimulation on T cell-mediated tumour immunity. J Exp Med 179:523
7. + T lymphocytes during HIV-1 infection. J Acquired Immune Defiency Syndromes 7:245
8. 8. Creagan ET, Schaid DJ, Ahmann DL, Frytak S (1988) Recombinant interferons in the management of advanced malignant melanoma. Am J Clin Oncol 11:652
9. 9. Croft M, Dubey C (1997) Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol 17:89
10. 10. Denfeld R, Dietrich A, Wuttig C, Tanczos E, Weiss J, Vanscheidt, Schöpf, Simon J (1995) In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 62:259
11. 11. Farace F, Angevin E, Vanderplanke J, Escuidier B, Triebel F (1994) The decreased expression of CD3ζ chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 59:752
12. 12. Finke J, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs R, Wiltrout RH, O'Shea J, Kudoh S, Klein E, Bukowski RM, Ochoa C (1993) Loss of T-cell receptor ζ chain and p56 in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:5613
13. 13. Fontenau J-F, Le Drean E, Le Guiner S, Gervois N, Diez E, Jotereau F (1997) Heterogeneity of biologic responses of melanoma-specific CTL. J Immunol 159:2831
14. 14. Fu EJ, Arca MJ, Hain JM, Krinock R, Cameron MJ, Chang AE, Sondak VK (1997) Tumour-induced suppression of antitumour reactivity and depression of TCRζ expression in tumour draining lymph node lymphocytes: Possible relationship to the Th2 pathway. J Immunother 20:111
15. 15. Gunji Y, Hori S, Aoe T, Ochiai T, Isono K, Saito T (1994) High frequency of cancer patients with abnormal assembly of the T-cell receptor CD3 complex in peripheral blood T lymphocytes. Jpn J Cancer Res 85:1189
16. + T cells. World J Surg 19:352
17. 17. Harding FA, Mc Arthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607
18. 18. Hersey P, Si Z, Smith M, Thomas W (1994) Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer 58:527
19. 19. Hurwitz PJ (1991) Spontaneous regression of metastatic melanoma. Ann Plast Surg 26:403
20. 20. Hutchinson GH, Heinemann D, Symes MO, Williamson RCN (1981) Differential immune reactivity of tumour intrinsic and peripheral-blood lymphocytes against autoplastic colorectal carcinoma cells. Br J Cancer 44:396
21. 21. Håkansson A, Gustafsson B, Krysander L, Håkansson L (1996) Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon-alpha treatment. Br J Cancer 74:670
22. 22. Håkansson A, Gustafsson B, Krysander L, Håkansson L (1998) Effect of interferon-alpha on tumour-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 18:33
23. 23. Ishiyama T, Koike M, Kakimoto T, Akimoto Y, Tsuruoka N (1996) The presence of CD28-negative T cells in a patient with multicentric Castleman's disease. Ann Hematol 73:199
24. 24. Jarnicki AG, Fitzpatrick DR, Robinson BWS, Bielefeldt-Ohman H (1996) Altered CD3 chain and cytokine gene expression in tumour infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett 103:1
25. 25. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249
26. 26. Judge TA, Tang A, Turka LA (1996) Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol Res 15:38
27. 27. June CH, Ledbetter JA, Linsley PS, Thompson CB (1990) Role of the CD28 receptor in T-cell activation. Immunol Today 11:211
28. 28. Kang S, Barnhill RL, Mihm MC, Sober AJ (1993) Histologic regression in malignant melanoma: an interobserver concordance study. J Cutaneous Pathol 20:126
29. 29. Kono K, Salazar-Onfray F, Pettersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Andersson P, Kiessling R (1996) Hydrogen peroxide secreted by tumour-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumour-specific T-cell and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308
30. 30. Leger-Ravet M-B, Mathiot C, Portier A, Brandely M, Galanaud P, Fridman W-H, Emilie D (1994) Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2. Cancer Immunol Immunother 39:53
31. 31. Legha SS (1997) The role of Interferon α in the treatment of metastatic melanoma. Semin Oncol 24 [Suppl 4]:24
32. + T cells. J Immunol 149:949
33. 33. Lowin B (1995) Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol 198:1
34. 34. Matsuda M, Petersson M, Lenkei R, Taupin J-L, Magnusson I, Mellstedt H, Andersson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumour-infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of disease. Int J Cancer 61:765
35. + cytotoxic T cells. Immunol Res 15:126
36. 36. Mc Govern VJ (1975) Spontaneous regression of melanoma. Pathology 7:91
37. 37. Miescher S, Whiteside TL, Carrel S, Von Fliedner V (1986) Functional properties of tumour-infiltrating and blood lymphocytes in patients with solid tumours: effects of tumour cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899
38. 38. Mihm MC, Clemente CG, Cascinelli N (1996) Tumour infiltrating lymphocytes in lymph node melanoma metastases: a histophathologic prognositc indicator and an expression of local immune response. Lab Invest 74:43
39. 39. Mizoguchi H, O'Shea J, Longo DL, Loeffler CM, Mc Vicar DW, Ochoa C (1992) Alterations in signal transduction molecules in T lymphocytes from tumour-being mice. Science 258:1795
40. 40. Mulder WMC, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ (1997) T cell receptor-z and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113
41. 41. Nakagomi H, Pettersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Andersson P, Kiessling R (1993) Decreased expression of the signal-transducing ζ chains in tumour-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610
42. 42. Nakanishi H, Monden T, Morimoto H, Kobayashi T, Shimano T, Mori T (1991) Perforin expression in lymphocytes infiltrated to human colorectal cancer. Br J Cancer 64:239
43. 43. Ohtani M, Naito Y, Saito K, Nagura H (1997) Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumour immunity? Lab Invest 77:231
44. 44. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T (1996) Oxidative stress by tumour derived macrophages suppresses the expression of CD3ζ chain of T-cell receptor complex and antigen specific T-cell responses. Proc Natl Acad Sci USA 93:13119
45. 45. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside T (1996) Expression and activity of signal molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 2:1263
46. 46. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK (1987) Thin malignant melanomas with regression and metastases. Arch Dermatol 123:1326
47. 47. Rossi E, Matutes E, Morilla R, Owusu-Ankomah K, Heffernan AM, Catovsky D (1996) Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 10:494
48. + independent T-cell mediated cytotoxicity. J Exp Med 177:195
49. 49. Sondergaard K, Hou-Jensen K (1985) Partial regression in thin primary cutaneous malignant melanomas clinical stage I. Virchows Arch [A] 408:241
50. 50. Tefany FJ, Barenetson R StC, Halliday GM, McCarthy SW, McCarthy WH (1991) Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97:197
51. + T cells from HIV-infected subjects. Clin Exp Immunol 100:425
52. 52. Vose BM, Moore M (1982) Mitogen responsiveness and inhibitory activity of mesenteric lymph node cells. Cancer Immunol Immunother 13:105
53. 53. Wojtowicz-Praga S (1997) Reversal of tumour-induced immunosuppression: a new approach to cancer therapy. J Immunother 20:165
54. 54. Zea AH, Curti BD, Longo DL, Avord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327